Discover
AUPH
Aurinia Pharmaceuticals Inc.
15.80
1 x 13.91
1 x 18.30
bid
ask
-
1.17
6.89%
1 @ 05:36 AM
15.88 +0.08 (0.51%)
| Ytd | -0.94% | |
| 1y | 111.23% |
15.78
day range
17.12
7.29
52 week range
19.25
| Open | 16.97 | Prev Close | 16.97 | Low | 15.78 | High | 17.12 | Mkt Cap | 2.03B |
| Vol | 2.02M | Avg Vol | 1.41M | EPS | 2.16 | P/E | 7.31 | Forward P/E | 14.13 |
| Beta | 1.43 | Short Ratio | 7.72 | Inst. Own | 60.26% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-30 | 50-d Avg | 15.99 | 200-d Avg | 14.78 | 1yr Est | 17.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-07 | 2026-03 | 0.18 | 0.25 | 0.07 | 38.89% |
| 2026-02-26 | 2025-12 | 0.21 | 0.26 | 0.05 | 23.81% |
| 2025-11-04 | 2025-09 | 0.16 | 0.23 | 0.07 | 43.75% |
| 2025-07-31 | 2025-06 | 0.17 | 0.16 | -0.01 | -5.88% |
| 2025-05-12 | 2025-03 | 0.08 | 0.16 | 0.08 | 100.00% |
| 2025-02-27 | 2024-12 | 0.03 | 0.09 | 0.06 | 200.00% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2025-12-03 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2025-11-07 | Jefferies | Upgrade | Hold | Buy |
| 2025-11-05 | RBC Capital | Downgrade | Outperform | Sector Perform |
| 2025-08-01 | RBC Capital | Upgrade | Outperform | Outperform |
| 2024-09-16 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
| 2024-09-09 | Cantor Fitzgerald | Upgrade | Overweight | Overweight |
Profile
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-05-17 | COLE RYAN | Chief Operating Officer | 116.14K | Stock Award(Grant) |
| 2026-02-26 | DONLEY MATTHEW MAXWELL | Chief Operating Officer | 680.30K | Stock Award(Grant) |
| 2026-02-26 | GREENLEAF PETER S | Chief Executive Officer | 1.84M | Stock Award(Grant) |
| 2024-08-05 | HABIG SCOTT MICHAEL | Officer | 456.34K | Sale |
| 2026-05-17 | HEARNE MICHAEL S. | Chief Financial Officer | 116.14K | Stock Award(Grant) |
| 2024-11-20 | JAYNE DAVID ROLAND WALKER | Director | 56.50K | Stock Award(Grant) |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Tang Capital Management, LLC | 12.23M | 193.23M | 9.51% |
| 2026-03-30 | Blackrock Inc. | 7.85M | 123.96M | 6.10% |
| 2026-03-30 | NEA Management Company, LLC | 3.97M | 62.72M | 3.09% |
| 2026-03-30 | Two Sigma Investments, LP | 3.43M | 54.17M | 2.67% |
| 2026-03-30 | Arrowstreet Capital, Limited Partnership | 3.28M | 51.89M | 2.55% |
| 2026-03-30 | State Street Corporation | 2.53M | 39.93M | 1.97% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | iShares Trust-iShares Russell 2000 ETF | 2.81M | 44.40M | 2.19% |
| 2026-04-29 | Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.18M | 18.63M | 0.92% |
| 2026-04-29 | iShares Trust-iShares Russell 2000 Growth ETF | 978.01K | 15.45M | 0.76% |
| 2026-04-29 | iShares Trust-iShares Biotechnology ETF | 869.39K | 13.74M | 0.68% |
| 2026-02-27 | VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 591.37K | 9.34M | 0.46% |
| 2026-04-29 | Janus Detroit Street TRT-Janus Henderson Small/Mid Cap Growth Alpha ET | 539.37K | 8.52M | 0.42% |